The first relapse in multiple myeloma: how to pick the next best thing

被引:1
作者
Devarakonda, Srinivas [1 ]
Sharma, Nidhi [1 ]
Efebera, Yvonne [2 ,3 ]
机构
[1] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH USA
[2] OhioHealth, Div Blood & Marrow Transplantat, Columbus, OH USA
[3] OhioHealth, 500 Thomas Ln, Columbus, OH 43214 USA
关键词
STEM-CELL TRANSPLANTATION; OPEN-LABEL; LENALIDOMIDE MAINTENANCE; DOUBLE-BLIND; DEXAMETHASONE; CARFILZOMIB; SURVIVAL; DARATUMUMAB; BORTEZOMIB; IXAZOMIB;
D O I
10.1182/hematology.2022000356
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
The choice of treat ment for patients with mul ti ple mye loma (MM) at fi rst relapse / pro gres sion is based on many fac tors: (1) treat ment - related fac tors, which include the reg i men used dur ing first induc tion, the qual ity and dura tion of first response achieved, toxicities from the first treat ment, whether the patient under went autol o gous stem cell trans plant, and whether the patient was on main te nance at the time of relapse / pro gres sion; (2) dis ease - related fac tors, includ ing dis ease pre sen ta tion and pace of pro gres sion; and (3) patient - related fac tors, includ ing func tional age and per for mance sta tus. The learn ing objec tives are to pres ent the treat ment options for patients with MM upon their fi rst relapse and to learn about various strategies for selecting an optimal treatment regimen.
引用
收藏
页码:560 / 568
页数:9
相关论文
共 49 条
  • [1] Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma
    Abbi, Kamal Kant Singh
    Zheng, Junting
    Devlin, Sean M.
    Giralt, Sergio
    Landau, Heather
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (03) : 468 - 472
  • [2] Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma
    Abdallah, Al-Ola
    Sigle, Monia
    Mohyuddin, Ghulam Rehman
    Coggins, Emily
    Remker, Cassie
    Shune, Leyla
    Mahmoudjafari, Zahra
    McGuirk, Joseph
    Ganguly, Siddhartha
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02) : E220 - E226
  • [3] Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
    Avet-Loiseau, Herve
    Bahlis, Nizar J.
    Chng, Wee-Joo
    Masszi, Tamas
    Viterbo, Luisa
    Pour, Ludek
    Ganly, Peter
    Palumbo, Antonio
    Cavo, Michele
    Langer, Christian
    Pluta, Andrzej
    Nagler, Arnon
    Kumar, Shaji
    Ben-Yehuda, Dina
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Berg, Deborah
    Lin, Jianchang
    van de Velde, Helgi
    Esseltine, Dixie-Lee
    di Bacco, Alessandra
    Moreau, Philippe
    Richardson, Paul G.
    [J]. BLOOD, 2017, 130 (24) : 2610 - 2618
  • [4] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Bahlis, Nizar J.
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Ukropec, Jon
    Qi, Ming
    San-Miguel, Jesus
    [J]. LEUKEMIA, 2020, 34 (07) : 1875 - 1884
  • [5] The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
    Cook, Gordon
    Ashcroft, A. John
    Cairns, David A.
    Williams, Cathy D.
    Brown, Julia M.
    Cavenagh, Jamie D.
    Snowden, John A.
    Parrish, Christopher
    Yong, Kwee
    Cavet, Jim
    Hunter, Hannah
    Bird, Jenny M.
    Pratt, Guy
    Chown, Sally
    Heartin, Ernest
    O'Connor, Sheila
    Drayson, Mark T.
    Hockaday, Anna
    Morris, Treen C. M.
    [J]. LANCET HAEMATOLOGY, 2016, 3 (07): : E340 - E351
  • [6] SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
    Deckert, Jutta
    Wetzel, Marie-Cecile
    Bartle, Laura M.
    Skaletskaya, Anna
    Goldmacher, Victor S.
    Vallee, Francois
    Zhou-Liu, Qing
    Ferrari, Paul
    Pouzieux, Stephanie
    Lahoute, Charlotte
    Dumontet, Charles
    Plesa, Adriana
    Chiron, Marielle
    Lejeune, Pascale
    Chittenden, Thomas
    Park, Peter U.
    Blanc, Veronique
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4574 - 4583
  • [7] Role of Stem Cell Transplantation in Multiple Myeloma
    Devarakonda, Srinivas
    Efebera, Yvonne
    Sharma, Nidhi
    [J]. CANCERS, 2021, 13 (04) : 1 - 19
  • [8] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Dimopoulos, M. A.
    Oriol, A.
    Nahi, H.
    San-Miguel, J.
    Bahlis, N. J.
    Usmani, S. Z.
    Rabin, N.
    Orlowski, R. Z.
    Komarnicki, M.
    Suzuki, K.
    Plesner, T.
    Yoon, S. -S.
    Ben Yehuda, D.
    Richardson, P. G.
    Goldschmidt, H.
    Reece, D.
    Lisby, S.
    Khokhar, N. Z.
    O'Rourke, L.
    Chiu, C.
    Qin, X.
    Guckert, M.
    Ahmadi, T.
    Moreau, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) : 1319 - 1331
  • [9] Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
    Dimopoulos, Meletios
    Weisel, Katja
    Moreau, Philippe
    Anderson, Larry D., Jr.
    White, Darrell
    San-Miguel, Jesus
    Sonneveld, Pieter
    Engelhardt, Monika
    Jenner, Matthew
    Corso, Alessandro
    Duerig, Jan
    Pavic, Michel
    Salomo, Morten
    Casal, Eva
    Srinivasan, Shankar
    Yu, Xin
    Nguyen, Tuong Vi
    Biyukov, Tsvetan
    Peluso, Teresa
    Richardson, Paul
    [J]. LEUKEMIA, 2021, 35 (06) : 1722 - 1731
  • [10] Dimopoulos M, 2020, LANCET, V396, P186, DOI 10.1016/S0140-6736(20)30734-0